Osterman Mark G 4
4 · DISCOVERY LABORATORIES INC /DE/ · Filed Jan 5, 2006
Insider Transaction Report
Form 4
Osterman Mark G
SVP, Sales and Marketing
Transactions
- Award
Common Stock
2005-10-21$6.45/sh+271$1,748→ 1,074 total - Award
Common Stock
2006-01-03+6,000→ 7,074 total - Award
Incentive Stock Option (right to buy)
2006-01-03+47,585→ 47,585 totalExercise: $7.01From: 2006-01-03Exp: 2016-01-03→ Common Stock (47,585 underlying) - Award
Non-Qualified Stock Option (right to buy)
2006-01-03+2,415→ 2,415 totalExercise: $7.01From: 2006-01-03Exp: 2016-01-03→ Common Stock (2,415 underlying) - Award
Common Stock
2005-07-21$6.46/sh+271$1,751→ 803 total
Footnotes (3)
- [F1]Transaction reported on Table I represents Issuer's matching stock contribution pursuant to 401(k) plan.
- [F2]New restricted stock award shall fully vest on the date that Surfaxin for RDS first becomes widely commercially available, as such date is determined by the Company.
- [F3]This employee stock option shall vest 25% on the date of the grant, and the balance shall vest in a series of three successive equal annual installments beginning with the first year anniversary of the grant.